ZGNX Overview
Upcoming Projects (ZGNX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (ZGNX)
-
Don’t see a project related to the company you care about? Create your own!
Expired Projects (ZGNX)
-
Discussing Zogenix’s FINTEPLA for the treatment of seizures associated with LGS: Ahead of the PDUFA set for March 25th
Tickers: ZGNX, UCB.XBRU
Execute By: Apr 30, 2022 -
With multiple options available for Dravet and Lennox Gastaut patients, how are prescribers changing practice?
Tickers: JAZZ, ZGNX
Execute By: Oct 15, 2021 -
Now that Zogenix's FINTEPLA is approved by the FDA, how does the label impact the commercial prospects of the drug?
Tickers: ZGNX, GWPH
Execute By: Aug 07, 2020
Upcoming & Overdue Catalysts (ZGNX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (ZGNX)
-
Zogenix Announces Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
Ticker: ZGNX
Occurred on: Sep 29, 2017 -
Zogenix (ZGNX) Expects Results From Phase 3 Study 1502 Evaluating ZX008 in Dravet Syndrome in Q1 2017
Tickers: ZGNX, GWPH
Occurred on: May 25, 2017 -
European Commission Designates Zogenix' (ZGNX) ZX008 an Orphan Medicinal Product for Lennox-Gastaut Syndrome
Ticker: ZGNX
Occurred on: Mar 01, 2017 -
Zogenix (ZGNX) Expects Phase 3 Study 1501 data for ZX008 in Dravet Syndrome in Late 2016
Tickers: ZGNX, GWPH
Occurred on: Dec 05, 2016 -
GW Pharma (GWPH) Expects to Present Phase 3 Data on Epidiolex at American Epilepsy Society Annual Meeting December 2-6
Tickers: GWPH, ZGNX
Occurred on: Dec 05, 2016 -
Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome
Ticker: ZGNX
Occurred on: May 05, 2016
Strategic Initiatives (ZGNX)
-
Zogenix (ZGNX) Makes Acquisition of Modis Therapeutics for its proprietary, late-stage investigational MT1621 targeting Thymidine Kinase 2 deficiency
Tickers: ZGNX, Modis Therapeutics
Announcement Date: Aug 26, 2019
